Osteoarthritis Drugs Market Analysis

Drug Type (Viscosupplementation Agents, Nonsteroidal anti-inflammatory Drugs, Analgesics, Corticosteroids)

Viscosupplementation agents’ segment is anticipated to capture around 34% osteoarthritis drugs market share by the end of 2037. Viscosupplementation agents effectively reduce pain, swelling, and stiffness, which makes them an effective choice for osteoarthritis treatment. Viscosupplementation agents particularly hyaluronic acid injects are administrated into the patients to enhance joint mobility, mitigate pain, and improve overall function. Key players in the market are investing in R&D to introduce advanced hyaluronic acid solutions for joint care. For instance, in July 2024, Bloomage BioTechnology Corporation Limited revealed its Hyaluronic Acid Research at IFT FIRST Expo 2024. The company also showcased UltraHA J, a hyaluronic acid product designed to support joint health.

Medication (Prescription Drugs, Over-the-counter (OTC) Drugs)

By the end of 2037, over-the-counter (OTC) osteoarthritis drugs segment is set to dominate around 55.5% osteoarthritis drugs market share. The easy access and widespread availability of OTC osteoarthritis drugs in retail pharmacies and supermarkets have made it convenient for patients to purchase these drugs. The online drug pharmacies’ growing awareness among people at large is also contributing to high sales of OTC osteoarthritis drugs. Online pharmacies offer attractive discounts and the availability of multiple brands including international products with reviews and recommendations appeals to patients, which further fuels the sales of OTC drugs.

Our in-depth analysis of the global market includes the following segments: